Researchers at the Indiana University School of Medicine will help study how certain genomic medicine interventions can improve management of diseases such as high blood pressure, depression and chronic pain, under a National Institutes of Health program.
The trials, which will begin in 2020, are part of a sweeping, five-year, $42 million federal research program known as Implementing Genomics in Practice. The first trial will examine whether early access to patients’ genomic data can help with treatment of high blood pressure, hypertension and chronic kidney disease.
The second trial will focus on pain and depression—two conditions where finding safe and effective drug treatments have been difficult, the medical school said.
Other research teams joining IU in the genomic trials are the University of Florida, Duke University, Vanderbilt University and the Icahn School of Medicine.•